This phenomenon is thought to result from compensatory mechanisms, such as increased SGLT1 activity and upregulation of SGLT2 expression
Preclinical studies using native GLP-1 or GLP-1RA have provided convincing evidence of its cardioprotective benefits, while clinical trials have shown positive effects on hypertension and dyslipidemia in patients with T2DM [3]
But the picture of weight loss medications for people with eating disorders and disordered eating patterns may be more complex than it seems
SGLT2 inhibitors may improve metabolic profiles in selected non-pregnant patients, but any such use must remain strictly outside pregnancy, under reliable contraception, and with guideline-consistent discontinuation before conception attempts because of urogenital adverse effects and contraindications during pregnancy (155, 156)
The addition of glucagon receptor activation introduces another variable that could theoretically affect fluid balance and salivary function, though specific data on retatrutide versus tirzepatide for dry mouth are not yet available
I have seen a case of that in our clinic
